Drug Trial Radar · NCT04449874
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
498
Planned (sponsor's estimate)
Start
Jul 29, 2020
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 29, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
Conditions
- Non-Small Cell Lung Cancer
- Colorectal Cancer
- Advanced Solid Tumors
Interventions
GDC-6036Drug
The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).
AtezolizumabDrug
A 1200 milligram (mg) intravenous (IV) infusion of atezolizumab will be administered on Day 1 of 21 day cycles.
CetuximabDrug
Cetuximab will be administered at an initial dose of 400 milligram per square meter (mg/m\^2) IV infusion followed by 250 mg/m\^2 IV infusion weekly in 21 day cycles.
BevacizumabDrug
A 15 milligram per kilogram (mg/kg) IV infusion of bevacizumab will be administered on Day 1 of 21 day cycles.
ErlotinibDrug
150 mg of erlotinib will be administered PO QD in 21 day cycles.
GDC-1971Drug
The starting dose of GDC-1971 will be determined from its single-agent dose escalation.
InavolisibDrug
The starting dose of inavolisib will be determined from its single-agent dose escalation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Adverse Events (AEs)Time frame: From Cycle 1 Day 1 until 28 days after the final dose (or as specified in the protocol). A cycle is 21 days.
- Percentage of Participants With Dose-Limiting Toxicities (DLTs)Time frame: From Cycle 1 Day 1 through Day 21. A cycle is 21 days.
Locations
63 sites in 17 countries. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California
UCSD Moores Cancer Center
La Jolla, California
Chao Family Comprehensive Cancer Center UCI
Orange, California
Yale Cancer Center
New Haven, Connecticut
Florida Cancer Specialists - Sarasota
Sarasota, Florida
Dana Farber Cancer Institute
Boston, Massachusetts
Memorial Sloan Kettering Cancer Center
New York, New York
University of Oklahoma
Oklahoma City, Oklahoma
UPMC - Hillman Cancer Center
Pittsburgh, Pennsylvania
Slade Health Inward goods
Mount Kuring-Gai, New South Wales, Australia
Peter MacCallum Cancer Center
Melbourne, Victoria, Australia
Alfred Health
Melbourne, Victoria, Australia
Linear Clinical Research Limited
Nedlands, Western Australia, Australia
UZ Antwerpen
Edegem, Belgium
CHU de Liège
Liège, Belgium
AZ St Maarten Campus Leopoldstr
Mechelen, Belgium
Instituto Nacional de Câncer
Rio de Janeiro, Brazil
Santa Casa de Misericordia de Belo Horizonte - PPDS
Belo Horizonte, Minas Gerais, Brazil
Hospital de Clinicas de Porto Alegre HCPA PPDS
Porto Alegre, Pará, Brazil
Hospital Erasto Gaertner
Curitiba, Paraná, Brazil
Universidade de Caxias do Sul
Caxias do Sul, Rio Grande do Sul, Brazil
Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)
Porto Alegre, Rio Grande do Sul, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS
São José do Rio Preto, São Paulo, Brazil
Ottawa Hospital
Ottawa, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Clinexpert Gyongyos Kft
Gyöngyös, Hungary
Rambam Medical Center
Haifa, Israel
Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel
Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS
Meldola, Emilia-Romagna, Italy
Irccs Ospedale San Raffaele
Milan, Lombardy, Italy
Asst Grande Ospedale Metropolitano Niguarda
Milan, Lombardy, Italy
Istituto Clinico Humanitas
Rozzano (MI), Lombardy, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, Tuscany, Italy
The Aga Khan University-Kenya.
Nairobi, Kenya
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands
Leids Universitair Medisch Centrum
Leiden, Netherlands
Maastricht University Medical Center
Maastricht, Netherlands
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands
Auckland City Hospital, Cancer and Blood Research
Auckland, New Zealand
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.